Supporting information
Supplementary Figure 1. Flow diagram of study.Click here for additional data file.Supplementary Figure 2. Probable mechanism of cardiovascular benefits of SGLT2 inhibitors. Hb, hemoglobin, HCT, hematocrit, BP, blood pressure.Click here for additional data file.Supplementary Figure 3. Probable anti‐anginal effect of empagliflozin, hemodynamic effect (A) metabolic effect (B).Click here for additional data file.